3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
17
Gastrointestinal Stromal Tumors
10
Neoplasms
5
Neoplasm Metastasis
4
Multiple Myeloma
4
Kidney Neoplasms
4
Urologic Neoplasms
2
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Kidney Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Methotrexate
6
Cyclophosphamide
6
ponatinib
5
Cytarabine
5
merphos
4
Mycophenolic Acid
4
blinatumomab
3
Whole-Body Irradiation
3
Tacrolimus
3
Peripheral Blood Stem Cell Transplantation
3
Cyclosporine
3
venetoclax
2
fludarabine phosphate
2
bosutinib
2
Vincristine
2
Rituximab
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Idarubicin
2
Etoposide
2
Cladribine
2
CT-P10
2
Busulfan
2
prednylidene
1
pegfilgrastim
1
nilotinib
1
midostaurin
1
gilteritinib
1
fludarabine
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Blast Crisis
×
Sunitinib
×
1 year
×
Clear all
No trials found.